ArticleBMJ open respiratory research2026
Pulmonary artery floating sign: a novel predictor of fatal haemoptysis in pulmonary mucormycosis and its early intervention strategy.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMassive haemoptysis is a life-threatening complication of pulmonary mucormycosis, often resulting from invasive destruction of pulmonary arteries. Early predictors and preventive strategies remain poorly defined.
methodsWe retrospectively enrolled all hospitalised patients with pulmonary mucormycosis regardless of haemoptysis between 2019 and 2024. Patients were stratified into non-massive and massive haemoptysis groups. Clinical and radiological variables were compared between groups, and univariable and multivariable logistic regression analyses were performed. Given the limited number of events and separation, Firth's penalised logistic regression and reduced multivariable models were used to identify robust predictors of massive haemoptysis. Additionally, we explored the feasibility of prophylactic pulmonary artery embolisation (PPAE) in a subset of high-risk patients to evaluate its potential role in preventing fatal haemorrhage.
resultsFifty-seven patients with pulmonary mucormycosis were enrolled, and 22 (38.6%) patients had massive haemoptysis, with a mortality rate of 72.7% (16/22). Cavity (68.2% vs 34.3%, p=0.026) and central necrosis (100% vs 74.3%, p=0.009) were significantly more common in the massive haemoptysis group. The pulmonary artery floating sign (PAFS) was observed in 81.8% (18/22) of the massive haemoptysis group versus 31.4% (11/35) of the non-massive haemoptysis group (p<0.001), and was the only independent predictor (adjusted OR 6.20, 95% CI 1.68 to 28.49). Five high-risk patients, including three with floating sign, underwent PPAE; only one subsequently died of bleeding.
conclusionThe PAFS is a novel and independent predictor of massive haemoptysis in pulmonary mucormycosis. Its early identification may support early risk stratification and inform consideration of PPAE in selected high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.